No Clinically Significant Interaction Between Metoprolol and Grapefruit
Metoprolol does not have a clinically significant interaction with grapefruit or grapefruit juice, and patients taking metoprolol do not need to avoid grapefruit products.
Metabolic Pathway Explains Lack of Interaction
Metoprolol is primarily metabolized by CYP2D6, not CYP3A4 1. This is the critical distinction that determines whether grapefruit poses a risk:
- Grapefruit juice inhibits CYP3A4 (and to some extent P-glycoprotein) in the intestinal wall and liver 2, 3
- Since metoprolol's metabolism does not depend on CYP3A4, grapefruit cannot meaningfully alter its blood levels
- The FDA drug label for metoprolol confirms it is "primarily metabolized by CYP2D6" and notes that "metoprolol is not a significant P-glycoprotein substrate" 1
Contrast With Drugs That DO Interact With Grapefruit
The evidence clearly shows which cardiovascular drugs require grapefruit avoidance:
Drugs metabolized by CYP3A4 that interact with grapefruit:
- Calcium channel blockers (diltiazem, verapamil, amlodipine, felodipine, nifedipine) 4, 5, 3
- Certain statins (simvastatin, lovastatin, atorvastatin) 3
- Amiodarone and dronedarone 5
- Disopyramide 5
Drugs NOT affected by grapefruit:
- Beta-blockers metabolized by CYP2D6 (metoprolol, propranolol) 6
- Drugs with non-CYP3A4 metabolism
The British Association of Dermatologists guideline explicitly warns patients on ciclosporin to "not eat grapefruit or drink grapefruit juice" because ciclosporin is a CYP3A4 substrate 2. No such warning exists for metoprolol in any guideline or drug label reviewed.
Clinical Bottom Line
Patients on metoprolol can safely consume grapefruit and grapefruit juice without concern for drug interaction. The restriction on grapefruit applies only to medications metabolized through the CYP3A4 pathway, which does not include metoprolol.